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Purpose: To screen for diabetic autonomic neuropathy of the pupil using 0.5% apraclonidine and 0.1% pilocarpine 
and to evaluate the early diagnostic value of this pharmacologic pupillary test by assessing the relationship between 
pupillary and cardiovascular autonomic neuropathies.
Methods: A total of 22 diabetic patients were recruited. Baseline pupillary diameter (PD) and the difference in PD 
between the test eye and the control eye before and after instillation of apraclonidine and pilocarpine were measured. 
All patients also underwent cardiovascular autonomic function (CAF) testing.
Results: Baseline PD in room light correlated with duration of diabetes mellitus (DM, p=0.049) and the presence of 
DM retinopathy (DMR, p=0.022). Eleven patients (50%) had positive apraclonidine tests, and two patients had 
positive pilocarpine tests. The patients who had positive pilocarpine tests also had positive apraclonidine tests. Patients 
who had a positive pupillary test had a significantly higher rate of positive CAF tests (p=0.032).
Conclusions: Pupillary autonomic neuropathy was related to the duration of diabetes and the degree of DMR. There 
was also a significant correlation between pupillary autonomic neuropathy and cardiovascular autonomic neuropathy 
(CAN). Also, sympathetic nerve dysfunction occurred prior to parasympathetic dysfunction in this study. A simple phar-
macologic pupillary test can help manage complications in diabetic patients because patients with pupillary autonomic 
dysfunction have an increased risk of CAN.
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Diabetic autonomic neuropathy (DAN) is one of the com-
plications of both types of diabetes mellitus, developing slowly 
over many years.
1  It can affect any part of the autonomic 
nervous system, including the cardiovascular, neurovascular, 
gastrointestinal, and genitourinary systems,
2  and it can in-
crease the mortality risk of diabetic patients.
3-5 The Diabetes 
Complications and Control Trial
6 found that intense 
glycemic control can prevent DAN, and other studies have 
shown that early-stage DAN can be reversed with intense 
glycemic control.
7,8 Therefore, screening for autonomic dys-
function is important in the long-term care of diabetic pa-
tients. The expression pattern of DAN, however, is highly 
variable, and it is difficult to detect this disease on routine 
physical examination.
Cardiovascular autonomic neuropathy (CAN) is one ma-
nifestation of DAN that causes abnormalities in heart rate 
control and vascular dynamics,
9 including resting tachycardia, 
postural hypotenics,, and exercise intolerance, and also causes 
an increased incindnce of silent myocardial infarction. A meta- 
analysis of 15 different studies cdynamdypothat the pooled 
estimate of  myocave mortality risk was 2.14 in diabetic patients 
with CAN compared to subjects who had normal baseline 
assessments.
10 
The pupil is solely regulated by the autonomic nervous 
system. Many pharmacologic tests have been established for 
diagnosing various pupillary abnormalities. Apraclonidine is 
primarily an α2-receptor agonist that induces pupillary miosis 
in a normal pupil. However, apraclonidine does exhibit some 
weak α1-affinity
11 and is known to cause mydriasis in patients 
with Horner’s syndrome who demonstrate postsynaptic α1- 
receptor sympathetic denervation supersensitivity in the pupil 
dilator muscle due to loss of normal sympathetic innervation.
11 
A recent study used 0.5% apraclonidine to screen for pupillary 
sympathetic denervation in diabetes, identifying a defect in 
nearly half of the diabetic patients.
12
Similarly, it is well known that the tonic pupil, which ex-
hibits postganglionic parasympathetic denervation supersen-
sitivity, constricts in response to 0.1% pilocarpine. Parasym-
pathetic denervation supersensitivity has also been demon-
strated in diabetic patients.
13
In this study, we used 0.5% apraclonidine and 0.1% pi-
locarpine to screen for sympathetic and parasympathetic 
denervation supersensitivity, respectively, in diabetic patients Korean J Ophthalmol Vol.23, No.4, 2009
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Fig. 1. Baseline PD (mm) in room light according to severity of dia-
betic retinopathy (r=‐0.48, p=0.022, Spearman correlation).
PD=pupillary diameter; NPDR=non-proliferative diabetic  retin-
opathy; PDR=proliferative diabetic retinopathy.
Fig. 2. Difference in PD between test eyes and control eyes follow-
ing 0.5% apraclonidine instillation according to severity of diabetic 
retinopathy (r=0.548, p=0.008, Spearman correlation).
PD=pupillary diameter; NPDR=non-proliferative diabetic  retin-
opathy; PDR=proliferative diabetic retinopathy.
in addition to evaluating the early diagnostic value of this 
pharmacologic pupillary test by assessing its relationship 
with CAN. Moreover, we investigated the correlation between 
the pupillary test and both the duration of diabetes and the 
severity of diabetic retinopathy (DMR).
Materials and Methods
A total of 22 patients with type 1 or type 2 diabetes were 
recruited for this study. All patients provided informed con-
sent. Patients were excluded if they were receiving any medi-
cal treatment that influenced pupillary reaction (i.e., ß-blockers, 
α-agonists, sympathomimetics, or cholinergics). Previous in-
traocular surgery history, retinal laser treatment history, and 
ocular pathologic conditions other than diabetic retinopathy 
were also exclusion criteria for this study.
At the beginning of the study, a basic ophthalmological 
evaluation was performed, including historical questioning 
regarding diabetes and other systemic conditions, visual acuity 
testing, a slit lamp examination, and a pupillary pharmacologic 
test. The details of the pupillary pharmacologic tests are as 
follows.
Pupil diameter (PD) was measured using a digital camera 
(Canon EOS 400D digital; Canon, Tokyo, Japan). Accom- 
modation was controlled by instructing the subjects to fix- 
ate on a 3-m-distant target. Baseline PD measurements in 
room light (200 lux) and darkness (0.25 lux) were meas- 
ured. The pharmacologic test of the parasympathetic system 
was performed first; 0.1% pilocarpine was instilled in one 
eye and 0.9% normal saline was instilled in the opposite 
eye as a control. The test eye was randomly selected. 
While waiting for an hour, patients were asked not to do 
any work requiring the use of near vision. PD was meas- 
ured in the dark one hour after instillation. Pharmacologic 
testing of the sympathetic system was performed four 
days later to ensure complete wash out of the pilocarpine. 
PD was measured in the dark both before and 1 hour after 
instillation of 0.5% apraclonidine in the test eye and 0.9% 
normal saline in the control eye. Photographs were 
transmitted to a computer and PD was calculated. Mea- 
surements and analyses were conducted by one examiner. 
In order to minimize the influence of patient condition and 
environmental variables, the difference in PD between the 
test eye and the control eye before and after eyedrop 
instillation was used for the primary data analysis. A diff- 
erence in PD of more than 1 mm was defined as a positive 
result for both the pilocarpine and apraclonidine tests.
After completion of the apraclonidine test, both fundi were 
examined with an indirect ophthalmoscope. The severity of 
retinopathy was classified according to the modified Early 
Treatment Diabetic Retinopathy Study severity scale into the 
following categories: no DMR, non-proliferative diabetic 
retinopathy (NPDR), and proliferative diabetic retinopathy 
(PDR). 
Cardiovascular autonomic function (CAF) tests were per-
formed to evaluate CAN. There are currently no generally 
accepted definitions or diagnostic methods for identifying 
CAN. In general, several abnormal results of various CAF 
tests are used as diagnostic criteria for CAN.
14 
We carried out four types of CAF tests, with more than 
two abnormal results being considered diagnostic for CAN. HJ Kwon and HY Kim. PUPILLARY TEST IN THE DIAGNOSIS OF DAN
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Fig. 3. Patient who had a positive pharmacologic test. (A) Baseline 
photograph. (B) After instillation of 0.1% pilocarpine in the left eye 
and 0.9% normal saline in the right eye. (C) After instillation of 0.5%
apraclonidine in the left eye and 0.9% normal saline in the right eye.
Table 1. Baseline characteristics and the results of the autonomic function tests and pupillary tests
Sex Age
(yr)
DM history
(yr)
CAF test 
result Retinopathy Baseline pupil 
diameter (mm)
Response to
pilocarpine
* (mm)
Response to 
apraclonidine
* (mm)
M 30 0 Negative No DMR  4.48 -0.14 0.55
F 52 0 Negative No DMR 3.86 -0.15 -0.49
F 25 0 Negative No DMR 5.6 -0.4 -0.36
M 44 0 Negative No DMR 5.56 -0.38 0.88
F 42 14 Negative NPDR 4.55 -0.04 1.39
†
F 64 3 Negative No DMR 3.78 -0.36 0.28
M 50 0 Negative No DMR 4.79 -0.05 -0.07
F 53 7 Positive No DMR 3.61 0.15 2.53
†
M 52 10 Positive No DMR 5.67 0.04 0.79
M 65 13 Positive NPDR 2.17 -0.57 2.66
†
M 45 15 Positive NPDR 4.07 -2.4
† 1.3
†
M 26 0 Positive No DMR 5 0.16 0.05
M 65 28 Positive NPDR 3.71 -1.82
† 1.54
†
F 52 10 Positive NPDR 2.5 -0.26 1.03
†
F 68 20 Positive No DMR 4.71 -0.29 0.07
F 60 17 Positive No DMR 3.51 -0.25 1.75
†
M 52 0 Positive No DMR 3.61 -0.33 0.54
M 48 0 Positive No DMR 3.79 0.02 1.22
†
F 66 20 Positive NPDR 3.53 -0.05 0.39
M 71 15 Positive No DMR 3.44 -0.14 1.03
†
M 31 5 Positive No DMR 4.23 -0.18 2.1
†
M 39 12 Positive PDR 3.21 0.28 2.11
†
M=male, F=female;  DM=diabetes mellitus;  CAF=cardiovascular autonomic function;  DMR=diabetic retinopathy, NPDR=non-proliferative
diabetic retinopathy, PDR=proliferative diabetic retinopathy.
*Difference in pupillary diameter (test eye-control eye); 
†Positive result in pupil test. 
The tests included 1) measurement of heart rate (HR); 2) 
systolic blood pressure (BP) response to standing; 3) beat- 
to-beat heart rate variation; and 4) BP response to a Valsalva 
maneuver. These diagnostic tests of cardiovascular reflexes 
are known to be sensitive, reproducible, and simple; they also 
allow extensive evaluation of diabetic CAN.
2
HR response to standing: The R-R interval (the time 
elapsing between two consecutive R waves in the electrocar-
diogram) was measured at beat 15 and beat 30 upon standing 
after 3 minutes of lying supine. A 30 : 15 ratio of less than 
1.03 was considered abnormal.
Systolic BP response to standing: Systolic BP was 
measured when the patient was supine and again 2 minutes 
after standing. A fall of more than 30 mmHg was con-
sidered abnormal.
Beat-to-beat HR variation: The patient laid supine and 
breathed at a rate of six breaths per minute. A difference in 
HR of less than ten beats per minute was considered 
abnormal.
HR response to Valsalva maneuver: The longest R-R 
interval following the Valsalva maneuver and the shortest 
R-R interval during the maneuver defined the Valsalva ratio 
(VR). A VR value greater than 1.17 was considered abnormal.
We used SPSS ver. 11.0 (SPSS Inc., Chicago, IL, USA) 
for statistical analysis. The average PDs in room light for 
both positive and negative apraclonidine tests were compared 
using the Mann-Whitney test. The relationship between the 
apraclonidine test and the CAF tests was evaluated with 
Fisher’s exact test. The relationships between PD and both the Korean J Ophthalmol Vol.23, No.4, 2009
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duration of diabetes mellitus (years) as well as the presence 
of DMR were evaluated using Spearman’s rank correlation 
coefficient.
Results
The mean age of the 22 patients who were included in 
this study was 56 years (range, 25 to 71 years), and the mean 
duration of diabetes was 8.96 years (range, 0 to 28 years). 
Six patients were receiving insulin to control blood sugar, 
15 patients were taking oral hypoglycemic agents, and 
one patient was not taking medication. Fundus examination 
showed that 15 patients had no DMR, six patients had 
NPDR, and one patient had PDR.
There was a significant correlation between the baseline 
PD (mm) in room light and the duration of diabetes (years) 
on direct analysis (r=-0.424, p=0.049, Spearman correlation). 
The baseline PD in room light also correlated with the severity 
of DMR (r=-0.485, p=0.022, Spearman correlation) (Fig. 1). 
After instillation of 0.1% apraclonidine, the mean difference 
in PD was 0.97 mm (range, -0.49 to 2.66 mm). Eleven patients 
(50%) showed differences of more than 1 mm (positive 
apraclonidine test). Interestingly, these patients had smaller 
PD measurements in room light than did the patients with 
negative tests (p=0.005, Mann-Whitney test). The differ- 
ence in PD (mm) after 0.5% apraclonidine instillation was 
also significantly correlated with the presence of DMR 
(r=0.548,  p=0.008, Spearman correlation) (Fig. 2).
The mean difference in PD (mm) after 0.1% pilocarpine 
instillation was -0.33 mm (range, -2.4 to 0.28 mm). Only two 
patients showed differences of more than 1 mm; these two 
patients also had positive apraclonidine tests (Fig. 3).
In CAF testing, 15 patients had positive results. Of these 
15 patients, ten patients had positive apraclonidine tests. Of 
the seven patients who had negative CAF tests, only one 
patient had a positive apraclonidine test. Ten of the 11 patients 
who had positive pupillary tests also had positive CAF tests 
(Table 1). Patients who had positive apraclonidine tests had 
a significantly higher rate of positive results in CAF testing 
(p=0.032, Fisher’s exact test). 
Discussion
The most common pupillary sign in diabetes is miosis.
15 
A number of previous studies have demonstrated that patients 
with a longer duration of diabetes have smaller pupils
16-19  and 
that there is a statistically significant association between small 
pupils and the severity of retinopathy.
20  We also ascertained 
a relationship between smaller pupils and both the duration 
of diabetes mellitus and presence of retinopathy in this study.
It has been suggested that failure of sympathetically- 
mediated pupil dilation is the mechanism of reduced pupil 
size in diabetics.
16,21  We confirmed this using the 0.5% apra-
clonidine test. Eleven patients who had positive apraclonidine 
tests had significantly smaller pupils than did patients with 
negative tests. Moreover, the degree of mydriasis in diabetics 
correlated with the severity of DMR. In this study, we ob-
served a high prevalence (50%) of sympathetic pupillary 
denervation in diabetes and a significant relationship between 
the pupil test and the duration of diabetes. 
Several studies have suggested that sympathetic autonomic 
dysfunction occurs before parasympathetic dysfunction in 
diabetes.
16,21,22 Our study confirmed this hypothesis. Of 11 
patients who had positive apraclonidine tests, only two patients 
also had positive pilocarpine tests. Although the reason for 
the greater susceptibility of the sympathetic nerves is not clear, 
one study has suggested that it may be due to the greater 
lengths of the sympathetic nerve pathways.
23 Histological 
studies have confirmed that nerve terminal loss occurs pre-
ferentially in the pupil dilator muscle, which is innervated by 
sympathetic nerves.
15
There are conflicting reports regarding whether or not pu-
pillary autonomic dysfunction is seen earlier than CAF.
13,18,24,25 
This discordance is probably due to a lack of standardization 
with regard to the diagnostic criteria and methods for identi-
fying CAN. In this study, ten of the 11 patients who had 
positive pupillary tests also had positive CAF tests, while 
five out of the 15 patients with positive CAF tests had nega-
tive pupillary tests. This could imply that cardiac autonomic 
changes precede pupillary autonomic nervous dysfunction. 
Although it is not clear whether pupillary dysfunction or car-
diovascular autonomic dysfunction occurs earlier, early detec-
tion of DAN is extremely important. DAN is often asymp-
tomatic in its early stages and is one of the least recognized 
complications of diabetes despite its significant negative im-
pact on survival and quality of life in diabetic patients.
2
In conclusion, our study showed that pupillary autonomic 
neuropathy was related to the duration of diabetes and degree 
of DMR. Pupillary autonomic neuropathy also demonstrated 
a significant correlation with CAN. Additionally, sympathetic 
nerve dysfunction occurred prior to parasympathetic dysfunc-
tion in this study. Given that patients with pupillary autonomic 
dysfunction have a higher risk for developing CAN, this 
simple pharmacologic pupillary test can help manage the 
complications of diabetes.
References
 
  1. Low PA. Diabetic autonomic neuropathy. Sem Neurol 1996;16: 
143-51.
  2. Vinik AI, Erbas T. Recognizing and treating  diabetic autonomic 
neuropathy. Cleve Clin J Med 2001;68:928-44.
  3. Ewing DJ, Boland O, Neilson JM, et al. Autonomic neuropathy, 
QT interval lengthening, and unexpected deaths in male diabetic 
patients. Diabetologia 1991;34:182-5.
  4. Rathmann W, Ziegler D, Jahnke M, et al. Mortality in diabetic 
patients with cardiovascular autonomic neuropathy. Diabet Med 
1993;10:820-4.
  5. O’Brian IA, McFadden JP, Corrall RJ. The influence of autonomic 
neuropathy on mortality in insulin-dependent diabetes. Q J Med 
1991;79:495-502.
  6. The effect of intensive diabetes therapy on the development and HJ Kwon and HY Kim. PUPILLARY TEST IN THE DIAGNOSIS OF DAN
295
progression of neuropathy. The Diabetes Control and Complications 
Trial Research Group. Ann Intern Med 1995;122:561-8.
  7. Hreidarsson AB. The pupil of the eye in diabetes mellitus, an 
indicator of autonomic nervous dysfunction. Dan Med Bull 1992; 
39:400-8.
  8. Terkildsen AB, Christensen NJ. Reversible nervous abnormalities 
in juvenile diabetics with recently diagnosed diabetes. Diabetologia 
1971;7:113-7.
  9. Purewal TS, Watkins PJ. Postural hypotension in diabetic neu-
ropathy: a review. Diabet Med 1995;12:192-200.
10. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuro- 
pathy. Circulation 2007;115:387-97.
11. Morales J, Brown SM, Abdul-Rahim AS, Crosson CE. Ocular 
effects of apraclonidine in Horner syndrome. Arch Ophthalmol 
2000;118:951-4.
12. Koc F, Kansu T, Kavuncu S, Firat E. Topical apraclonidine testing 
discloses pupillary sympathetic denervation in diabetic patients. 
J Neuroophthalmol 2006;26:25-9.
13. Cahill M., Eustace P, de Jesus V. Pupillary autonomic denervation 
with increasing duration of diabetes mellitus. Br J Ophthalmology 
2001;85:1225-30.
14. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic 
autonomic neuropathy. Diabetes Care 2003;26:1553-79.
15. Bremner FD, Smith SE. Pupil abnormalities in selected 
autonomic neuropathies. J Neuroophthalmol 2006;26:209-19.
16. Smith SE, Smith SA, Brown PM, et al. Pupillary signs in diabetic 
autonomic neuropathy. Br Med J 1978;2:924-7.
17. Hreidarsson AB. Pupil size in insulin-dependent diabetes: relation- 
ship to duration, metabolic control and long-term manifestations. 
Diabetes 1982;31:442-8.
18. Schwingshandl J, Simpson JM, Donaghue K, et al. Pupillary 
abnormalities in type I diabetes occurring during adolescence: 
comparisons with cardiovascular reflexes. Diabetes Care 
1993;16:630-3.
19. Straub RH, Thies U, Jeron A, et al. Valid parameters for inves-
tigation of the pupillary light reflex in normal and diabetic subjects 
shown by factor analysis and partial correlation. Diabetologia 
1994;37:414-9.
20. Hayashi M, Ishikawa S. Pharmacology of pupillary responses in 
diabetics - correlative study of the responses and grade of retinopathy. 
Jpn J Ophthalmol 1979;23:65-72.
21. Smith SA, Dewhirst RR. A simple diagnostic test for pupillary 
abnormality in diabetic autonomic neuropathy. Diabet Med 1986; 
3:38-41.
22. Smith SA, Smith SE. Evidence for a neuropathic aetiology in the 
small pupil of diabetes mellitus. Br J Ophthalmol 1983;67:89-93.
23. Smith SA, Smith SE. Reduced pupillary light reflex in diabetic 
autonomic neuropathy. Diabetologia 1983;24:330-2.
24. Barron SA, Rogovski Z, Kanter Y, Hemli Y. Parasympathetic auto-
nomic neuropathy in diabetes mellitus: the heart is denervated more 
often than the pupil. Electromyogr Clin Neurophysiol 1994;34: 
467-9.
25. Pittasch D, Lobmann R, Behrens-Baumann W, Lehnert H. Pupil 
signs of sympathetic autonomic neuropathy in patients with type 
1 diabetes. Diabetes Care 2002;25:1545-50.